Newron Pharmaceuticals S.p. A. is a biopharmaceutical company focused on the development of novel therapies for patients with diseases of the central and peripheral nervous system. Founded in 1999, Newron is headquartered in Bresso, near Milan, Italy, with a subsidiary in Morristown, NJ, USA. We have built a late-stage pipeline that currently includes one marketed product and wholly-owned product candidates in clinical development.
In addition to Xadago for Parkinson's disease, Newron has a strong pipeline of promising treatments including Evenamide as the potential first add-on therapy for the treatment of patients with positive symptoms of schizophrenia and ralfinamide for patients with specific rare pain indication.
In addition to Xadago for Parkinson's disease, Newron has a strong pipeline of promising treatments including Evenamide as the potential first add-on therapy for the treatment of patients with positive symptoms of schizophrenia and ralfinamide for patients with specific rare pain indication.
Services
Newron Pharmaceuticals S.p. A. is a biopharmaceutical company focused on the development of novel therapies for patients with diseases of the central and peripheral nervous system. Newron is a biopharmaceutical company focused on the development of novel therapies for patients with diseases of the central nervous system (CNS) and pain.
Newron is a biopharmaceutical company focused on the development of novel therapies for patients with diseases of the central nervous system (CNS) and pain. We are committed to delivering innovative treatments to improve the quality of life for patients with CNS disorders.
Our team has built a balanced and robust pipeline comprised of drug candidates at different clinical stages and has a proven track record of drug development and commercialization.Our balanced and robust pipeline is comprised of drug candidates targeting various indications in CNS and pain. Xadago (safinamide) is a New Chemical Entity for the treatment of Parkinson's Disease with a mode of action characterized by selective MAO-B-inhibition.
Our team has built a balanced and robust pipeline comprised of drug candidates at different clinical stages and has a proven track record of drug development and commercialization.Our balanced and robust pipeline is comprised of drug candidates targeting various indications in CNS and pain. Xadago (safinamide) is a New Chemical Entity for the treatment of Parkinson's Disease with a mode of action characterized by selective MAO-B-inhibition.
Newron's Board of Directors (the "Board") and management are committed to high standards of corporate governance, including transparency and accountability towards its share- holders as well as equal treatment of all shareholders. For more information on Newron's corporate governance, please see the relevant sections of our most recent Annual Report.
Newron shares are listed on the SIX Swiss Exchange and on Dsseldorf Stock Exchange as well as XETRA, one of the leading electronic trading platforms in Europe. We have a subscription form online in which you can register for news. Each time something new is published on our Investor Relations website you will receive an E-mail alert.
We are always interested in talking to candidates who would like a career in a dynamic and fast-moving biopharmaceutical company. Newron is expanding and we are always interested in talking to candidates who would like a career in a dynamic and fast-moving biopharmaceutical company. For additional info, please contact our Human Resources Department at info@newron.com.
Reviews
Be the first to review Newron Pharmaceuticals.
Write a Review
